Launched with $10 million in Series A financing from top-tier venture investors Third Rock Ventures and SV Life Sciences, Cibiem is leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company is testing its unique CBM physiological approach in first-in-man clinical trials.